2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

628. Aggressive Lymphomas: Cellular Therapies: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Clinical Procedures, Treatment Considerations, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Infusion, Non-Biological Therapies, Chemotherapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality of Care, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult
PAPER

1911 Glofitamab-based bridging followed by CAR-T cell therapy with or without ASCT in relapsed/refractory aggressive B-cell lymphoma: A prospective trial

Yi Wang, MD, Wei LIU2, Huimin Liu3, Hesong Zou4, Qi Wang, MD5, Rui Lv, MD6, Weiwei Sui7, Shuhui Deng8, Yan Xu, MD9, Wenjie Xiong10, Peiyuan Dong11, Liang Huang, MD12, Gang An, MD13, Lu-Gui Qiu, PhD14, Dehui Zou, MD15
1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology& Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
2 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology& Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
3 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology& Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
4 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology& Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
5 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology& Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
6 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology& Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
7 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology& Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
8 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology& Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
9 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology& Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
10 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology& Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
11 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology& Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
12 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology& Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
13 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology& Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
14 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology& Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
15 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology& Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China

Background: Bispecific antibodies (BsAbs) and chimeric antigen receptor T-cell (CAR-T) therapy have reshaped treatment paradigms for relapsed/refractory (R/R) aggressive B-cell lymphoma. Bridging therapy during CAR-T manufacturing is crucial to prevent disease progression and preserve patient fitness. Glofitamab, a CD20×CD3 bispecific antibody with rapid onset and chemotherapy-independent efficacy, is a promising bridging candidate. However, clinical evidence for BsAb bridging prior to CAR-T therapy, with or without autologous stem cell transplantation (CAR-T±ASCT), remains limited. Here, we prospectively evaluated the efficacy, safety, and clinical synergy of sequential glofitamab bridging and cellular therapy.

Methods: In this prospective trial (NCT06996132), patients with R/R aggressive B-cell lymphoma received glofitamab-containing bridging regimens—as monotherapy, or combined with immunochemotherapy or targeted agents—followed by CAR-T±ASCT. The choice between CAR-T alone and CAR-T+ASCT was individualized according to stem cell mobilization/collection status, age and performance status, and prior transplant history. The primary endpoint was complete response rate (CRR) post-CAR-T±ASCT. Response was evaluated using Lugano criteria, and cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) were graded via ASTCT consensus criteria across both treatment phases. Progression-free survival (PFS) and overall survival (OS) were calculated from bridging initiation using the Kaplan–Meier method.

Results: Between April 2024 and May 2026, 36 patients were enrolled. Median age was 54 years (range 21–75), with a male-to-female ratio of 5:4. High disease burden or high-risk features were prevalent: 88.9% Ann Arbor stage III–IV, 77.8% elevated lactate dehydrogenase, and TP53 mutation/deletion in 54.8% of evaluable patients (17/31). Patients had received a median of 2 prior lines (range 1–5). Bridging therapy consisted of glofitamab monotherapy in 9 patients (25.0%), glofitamab plus immunochemotherapy in 22 (61.1%), and glofitamab plus small-molecule/targeted agents in 5 (13.9%). Subsequently, 21 patients (58.3%) received CAR-T+ASCT and 15 (41.7%) received CAR-T alone. The objective response rate (ORR) after bridging was 94.4% (CRR 38.9%, partial response 55.6%). Following CAR-T±ASCT, the best ORR reached 100% with a best CRR of 86.1%. At a median follow-up of 10 months (range 2–29), 5 patients had disease progression and 2 died (1 from progression, 1 from a treatment-unrelated complication). Estimated 1-year PFS and OS were 72.6% and 90.4%, respectively. No grade ≥3 CRS occurred. During bridging, CRS was observed in 50.0% (18/36), with grade 2 in 5.6% (2/36). During CAR-T±ASCT, CRS occurred in 91.7% (33/36), with grade 2 in 2.8% (1/36). No ICANS developed during bridging; 1 patient (2.8%) had grade 3 ICANS following CAR-T±ASCT.

Conclusions: Glofitamab-based bridging before CAR-T±ASCT achieves deep, durable responses with favorable safety in R/R aggressive B-cell lymphoma. Sequential BsAb bridging and CAR-T+ASCT demonstrate strong clinical synergy without compounding severe immune toxicities, offering a viable strategy to optimize long-term outcomes.

Yi Wang, MD: No relevant conflicts of interest to declare.